/stocks — the workspaceLOADING
All RADX SEC filings, by type → · Earnings date & implied move · Search inside filings
RADX is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Radiopharm Theranostics Ltd (RADX) is a pharmaceutical preparations company. 1 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind RADX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has RADX been issuing shares? Offering history →
Volume against its own history: 2% of its last 252 sessions were lighter than the last one, the 2026-11-10 session. End-of-day bars (Databento). Volume detail
This company reports under IFRS, so its figures come from the ifrs-full taxonomy rather than US GAAP. Year to 2025-06-30, from the 20-F filed 2025-09-18, in USD as filed and never converted. Annual figures only: half-years on 6-K are not joined into a trailing year.
| Revenue | 3.6M USD No prior year in the same currency | ifrs-full Revenue |
| Gross profit | 39,276 USD 299,228 USD a year earlier (2024-06-30) | ifrs-full GrossProfit |
| Operating profit | -38.2M USD -47.2M USD a year earlier (2024-06-30) | ifrs-full ProfitLossFromOperatingActivities |
| Net income | -38.3M USD -47.9M USD a year earlier (2024-06-30) | ifrs-full ProfitLoss |
| Diluted EPS | -1.76 USD a share -12.41 USD a share a year earlier (2024-06-30) | ifrs-full DilutedEarningsLossPerShare |
| Total assets | 86.5M USD 72.0M USD a year earlier (2024-06-30) | ifrs-full Assets |
| Total liabilities | 43.6M USD 44.7M USD a year earlier (2024-06-30) | ifrs-full Liabilities |
| Shareholders’ equity | 42.9M USD 27.4M USD a year earlier (2024-06-30) | ifrs-full Equity |
| Cash and equivalents | 29.1M USD 18.6M USD a year earlier (2024-06-30) | ifrs-full CashAndCashEquivalents |
| Operating cash flow | -36.6M USD -23.0M USD a year earlier (2024-06-30) | ifrs-full CashFlowsFromUsedInOperatingActivities |
| Capital spending | Not tagged: the newest annual report files no PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities for this year in USD, so no figure is shown. | |
| Share-based payment | 1.9M USD 2.6M USD a year earlier (2024-06-30) | ifrs-full AdjustmentsForSharebasedPayments |
Not shown for IFRS filers: trailing-twelve-month figures, the F, Z and M scores, market cap and per-ADS figures. The coverage boundary, and why
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as RADX tagged it, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on RADX plus an auto-SWOT, built from RADX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate RADX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about RADX’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
Daily closes from 2024-12-10 through 2026-11-10, 475 sessions, split-adjusted (1 split applied), history before 2024-12-10 left out at a corporate action. No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in RADX’s filings; the chart with studies draws every figure.
Written by code from 475 end-of-day bars through 2026-11-10. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
Projected from RADX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentRADX files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Nothing on file for RADX from Nov 11, 2026 to Nov 24, 2026 in these sources: earnings date and filing deadline.
| Event | Result |
|---|---|
| Earnings date | nothing in the window. No date in the window: no regular report cadence in the filings. |
| Filing deadline | nothing in the window. Nothing in the window: the 20-F for the fiscal year ending Jun 30, 2027, due four months after it, falls due Nov 1, 2027, after it. Newest periodic report on file: the 20-F for the period ending Jun 30, 2026, filed Sep 30, 2026. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-11 to 2026-11-24, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
2 of the 2 checks that ran found nothing new for RADX. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
No fair value band on this page build. No annual filing figures reached the estimators, either because the SEC read did not finish or because RADX has not filed annual figures yet. That is a statement about the read, not about RADX’s value. The page rebuilds daily.
Every refusal recorded for RADX → · How often we decline, and why →
Total return including reinvested dividends, from RADX’s adjusted closing prices. Past return is not a forecast and not investment advice.
Group: Pharmaceutical Preparations, the SEC industry code RADX files under. 10 companies in our stored table file under it.
| Metric | RADX | Group median | 25th to 75th percentile | Where RADX sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | not placed | 21.4%⊙INFERENCE — derived by arithmetic SourceNet margin across the 10 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure. | 13.0% to 28.4% | RADX has no annual report in the stored table yet, so it has no figure to place. |
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | not placed | 20.9%⊙INFERENCE — derived by arithmetic SourceFree cash flow margin across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's operating cash flow less capital expenditure, divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 16.7% to 26.7% | RADX has no annual report in the stored table yet, so it has no figure to place. |
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | not placed | 32.9%⊙INFERENCE — derived by arithmetic SourceReturn on equity across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by stockholders’ equity at the fiscal year end, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 12.5% to 38.2% | RADX has no annual report in the stored table yet, so it has no figure to place. |
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Head office: Carlton VIC, Australia
Source: the cover page of Radiopharm Theranostics Ltd’s 20-F filed 2026-09-30, on EDGAR. Filings checked 2026-11-11. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No tracked institution reported a position in RADX in the latest 13F round.
No open-market Form 4 buys or sells reported for RADX in the last ~6 months.
No lawmaker has disclosed a trade in RADX under the STOCK Act.